share_log

Oppenheimer Initiates Coverage On Entrada Therapeutics With Outperform Rating, Announces Price Target of $22

Oppenheimer Initiates Coverage On Entrada Therapeutics With Outperform Rating, Announces Price Target of $22

奧本海默以跑贏大盤的評級開始對Entrada Therapeutics進行報道,宣佈目標股價爲22美元
Benzinga ·  01/05 07:23

Oppenheimer analyst Hartaj Singh initiates coverage on Entrada Therapeutics (NASDAQ:TRDA) with a Outperform rating and announces Price Target of $22.

奧本海默分析師哈塔傑·辛格以跑贏大盤的評級開始對Entrada Therapeutics(納斯達克股票代碼:TRDA)進行報道,並宣佈目標股價爲22美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論